Ticagrelor is more effective than clopidogrel in carrier of nonfunctional CYP2C19 allele who has diabetes and acute coronary syndrome - case report and literature review

Clopidogrel is a purinergic receptor P2Y12 (P2RY12)-blocking pro-drug used to inhibit platelet aggregation in patients at risk for major adverse cardiac events (MACE), such as coronary artery disease and stroke. Despite clopidogrel therapy, some patients may still present with recurrent cardiovascul...

Descripción completa

Detalles Bibliográficos
Autores principales: Tekeste, Rahel, Garza, Gregorio, Han, Song, Dong, Jianli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9140224/
https://www.ncbi.nlm.nih.gov/pubmed/35647265
http://dx.doi.org/10.3934/molsci.2022004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9140224/
https://www.ncbi.nlm.nih.gov/pubmed/35647265
http://dx.doi.org/10.3934/molsci.2022004

Ejemplares similares